Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Clin Immunol ; 43(8): 1724-1739, 2023 11.
Artigo em Inglês | MEDLINE | ID: mdl-37606852

RESUMO

COVID-19 vaccines have significantly decreased the number of severe cases of the disease, but the virus circulation remains important, and questions about the need of new vaccination campaigns remain unanswered. The individual's protection against SARS-CoV-2 infection is most commonly measured by the level and the neutralizing capacity of antibodies produced against SARS-CoV-2. T cell response is a major contributor in viral infection, and several studies have shown that cellular T cell response is crucial in fighting off SARS-CoV-2 infection. Actually, no threshold of protective immune response against SARS-CoV2 infection has been identified. To better understand SARS-CoV-2-mediated immunity, we assessed both B cell (measuring anti-Spike IgG titer and neutralization capacity) and T cell (measuring IFNγ release assay after specific SARS-CoV2 stimulation) responses to SARS-CoV-2 vaccination with or without virus encounter in a cohort of 367 working volunteers. Vaccinated individuals who had previously been infected had a stronger and more lasting immunity in comparison to vaccinated individuals naive to infection whose immunity started to decline 3 months after vaccination. IFNγ release ≥ 0.285 IU/mL and anti-Spike IgG antibodies ≥ 244 BAU/mL were associated with a sufficient immune response following vaccination preventing future infections. Individuals with comorbidities had a lower chance of reaching the protective thresholds of T cell and B cell responses as identified in multivariate analysis. A combined B cell and T cell analysis of immune responses to determine protective thresholds after SARS-CoV-2 vaccination will allow us to identify individuals in need of a booster vaccine dose, particularly in comorbid subjects.


Assuntos
COVID-19 , SARS-CoV-2 , Humanos , Estudos Prospectivos , COVID-19/epidemiologia , COVID-19/prevenção & controle , Vacinas contra COVID-19 , RNA Viral , França/epidemiologia , Imunidade Celular , Imunoglobulina G
2.
Sante Publique ; 33(5): 725-728, 2022.
Artigo em Francês | MEDLINE | ID: mdl-35724106

RESUMO

INTRODUCTION: In the SARS-CoV-2 epidemic, the monitoring of epidemiological surveillance indicators is a central issue. OBJECTIVE: We were able to describe the monitoring of the epidemic of hospitalized patients in the department of Alpes-Maritimes from three data sources: 1) Santé Publique France (SPF) via the SI-VIC software, 2) the Regional Health Agency (ARS Paca) with conventional hospitalization or department critical care data taken from SI-VIC, adjusting them to those of the Health Establishments (ES), 3) The ES of Alpes-Maritimes associated with the ARS of Alpes-Maritimes and the Department of Public Health (DSP) of the CHU, with the collection of patients hospitalized in the conventional sector or in critical/intensive care in the dedicated COVID-19 beds. The aim of this study was to verify the consistency of these three information systems. RESULTS: We observed disparities between the number of cases of hospitalization of SPF and the data from ES/ARS/DSP. We did not observe any differences in patients hospitized in intensive care/critical care units. The Scientific Council uses SPF data on the number of hospitalizations or intensive/critical beds to justify its recommendations.However, SPF data from SI-VIC have associated patients hospitalized for COVID and patients who tested positive for PCR, but whose reason for hospitalization is not related to SARS-CoV2 infection (formerly infected or asymptomatic patients). CONCLUSIONS: We believe that hospital surveillance indicators should only take into account the number of patients in conventional hospitalization or resuscitation for a COVID-19 infection.


Assuntos
COVID-19 , COVID-19/epidemiologia , Hospitalização , Humanos , Unidades de Terapia Intensiva , RNA Viral , SARS-CoV-2
3.
Front Immunol ; 14: 1145652, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37063916

RESUMO

Introduction: COVID-19 vaccines are expected to provide effective protection. However, emerging strains can cause breakthrough infection in vaccinated individuals. The immune response of vaccinated individuals who have experienced breakthrough infection is still poorly understood. Methods: Here, we studied the humoral and cellular immune responses of fully vaccinated individuals who subsequently experienced breakthrough infection due to the Delta variant of SARS-CoV-2 and correlated them with the severity of the disease. Results: In this study, an effective humoral response alone was not sufficient to induce effective immune protection against severe breakthrough infection, which also required effective cell-mediated immunity to SARS-CoV-2. Patients who did not require oxygen had significantly higher specific (p=0.021) and nonspecific (p=0.004) cellular responses to SARS-CoV-2 at the onset of infection than those who progressed to a severe form. Discussion: Knowing both humoral and cellular immune response could allow to adapt preventive strategy, by better selecting patients who would benefit from additional vaccine boosters. Trial registration numbers: https://clinicaltrials.gov, identifier NCT04355351; https://clinicaltrials.gov, identifier NCT04429594.


Assuntos
COVID-19 , Vacinas , Humanos , SARS-CoV-2 , Vacinas contra COVID-19 , Infecções Irruptivas , COVID-19/prevenção & controle
4.
Front Immunol ; 13: 953502, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36225915

RESUMO

The SARS-CoV-2 infection has spread rapidly around the world causing millions of deaths. Several treatments can reduce mortality and hospitalization. However, their efficacy depends on the choice of the molecule and the precise timing of its administration to ensure viral clearance and avoid a deleterious inflammatory response. Here, we investigated IFN-γ, assessed by a functional immunoassay, as a predictive biomarker for the risk of hospitalization at an early stage of infection or within one month prior to infection. Individuals with IFN-γ levels below 15 IU/mL were 6.57-times more likely to be hospitalized than those with higher values (p<0.001). As confirmed by multivariable analysis, low IFN-γ levels, age >65 years, and no vaccination were independently associated with hospitalization. In addition, we found a significant inverse correlation between low IFN-γ response and high level of IL-6 in plasma (Spearman's rho=-0.38, p=0.003). Early analysis of the IFN-γ response in a contact or recently infected subject with SARS-CoV-2 could predict hospitalization and thus help the clinician to choose the appropriate treatment avoiding severe forms of infection and hospitalization.


Assuntos
COVID-19 , Idoso , Biomarcadores , Hospitalização , Humanos , Interferon gama , Interleucina-6 , SARS-CoV-2
5.
EBioMedicine ; 85: 104291, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-36183487

RESUMO

BACKGROUND: While air pollution is a major issue due to its harmful effects on human health, few studies focus on its impact on the immune system and vulnerability to viral infections. The lockdown declared following the COVID-19 pandemic represents a unique opportunity to study the large-scale impact of variations in air pollutants in real life. We hypothesized that variations in air pollutants modify Th1 response represented by interferon (IFN) γ production. METHODS: We conducted a single center paired pilot cohort study of 58 participants, and a confirmation cohort of 320 participants in Nice (France), with for each cohort two samplings at six months intervals. We correlated the variations in the production of IFNγ after non-specific stimulation of participants' immune cells with variations in key regulated pollutants: NO2, O3, PM2.5, and PM10 and climate variables. Using linear regression, we studied the effects of variations of each pollutant on the immune response. FINDINGS: In the pilot cohort, IFNγ production significantly decreased by 25.7% post-lockdown compared to during lockdown, while NO2 increased significantly by 46.0%. After the adjustment for climate variations during the study period (sunshine and temperature), we observed a significant effect of NO2 variation on IFNγ production (P=0.03). In the confirmation cohort IFNγ decreased significantly by 47.8% and after adjustment for environmental factors and intrinsic characteristics we observed a significant effect of environmental factors: NO2, PM10, O3, climatic conditions (sunshine exposure, relative humidity) on variation in IFNγ production (P=0.005, P<0.001, P=0.001, P=0.002 and P<0.001 respectively) but not independently from the BMI at inclusion and the workplace P=0.007 and P<0.001 respectively). INTERPRETATION: We show a weakening of the antiviral cellular response in correlation with an increase of pollutants exposition. FUNDING: Agence Nationale de la Recherche, Conseil Départemental des Alpes-Maritimes and Region Sud.


Assuntos
Poluentes Atmosféricos , Poluição do Ar , COVID-19 , Humanos , Interferon gama , Dióxido de Nitrogênio/análise , Material Particulado/efeitos adversos , Material Particulado/análise , Estudos de Coortes , Pandemias , Projetos Piloto , COVID-19/epidemiologia , Controle de Doenças Transmissíveis , Poluição do Ar/efeitos adversos , Poluentes Atmosféricos/efeitos adversos , Poluentes Atmosféricos/análise , Exposição Ambiental/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA